Clinical Cancer Research Joint Metastasis Research Society-AACR Conference on Metastasis Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koster, A.
Right arrow Articles by Raemaekers, J. M.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koster, A.
Right arrow Articles by Raemaekers, J. M.M.
Clinical Cancer Research Vol. 11, 154-161, January 2005
© 2005 American Association for Cancer Research


Imaging, Diagnosis, Prognosis

Increased Vascularization Predicts Favorable Outcome in Follicular Lymphoma

Ad Koster1, Joannes H.J.M. van Krieken2, Marius A. MacKenzie1, Margit Schraders2, George F. Borm3, Jeroen A.W.M. van der Laak2, William Leenders2, Konnie Hebeda2 and John M.M. Raemaekers1

Departments of 1 Hematology, 2 Pathology, and 3 Epidemiology and Biostatistics, University Medical Centre Nijmegen, Nijmegen, the Netherlands

Requests for reprints: Ad Koster, Department of Hematology 544, University Medical Centre Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands. Phone: 31-2436-14762; Fax: 31-2435-42080; E-mail: a.koster{at}hemat.umcn.nl.

Purpose: In malignant lymphoma, angiogenesis has been associated with adverse outcome or more aggressive clinical behavior. This correlation has been established in groups of patients with a large heterogeneity regarding lymphoma subtypes and treatment regimens. The aim of this study is to investigate the significance of vascularization in patients with follicular lymphoma receiving uniform first-line treatment.

Experimental Design: We assessed microvessel density (MVD) in pretreatment lymph node biopsies of 46 previously untreated patients with follicular lymphoma using anti-CD34 immunohistochemical staining and interactive quantification. In a selection of cases, vascular endothelial growth factor (VEGF)-RNA in situ hybridization was done. Patients were treated with cyclophosphamide-vincristine-prednisone induction chemotherapy combined with IFN-{alpha}2b. Thirty-six patients responded and received IFN-{alpha} as maintenance therapy.

Results: MVD ranged from 10 to 70 per measurement field of 0.19 mm2 (median, 38). Median progression-free survival was 47 months in patients with MVD in the highest tertile and only 13 months in patients with lower MVD. Overall survival in patients with low vessel density was 59 months. In patients with high vessel density, median overall survival was not reached. Multivariate analysis indicated that MVD was independently associated with overall survival. There was a lack of correlation between VEGF-RNA expression and vessel density.

Conclusion: This study shows that in follicular lymphoma increased vascularization is associated with improved clinical outcome. Furthermore, VEGF-A expression seems not to be involved in follicular lymphoma angiogenesis.

Key Words: Follicular lymphoma • Microvessel density • Angiogenesis • VEGF




This article has been cited by other articles:


Home page
JCOHome page
D. Canioni, G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchhauser, T. Lamy, A. Sonet, M.-C. Rousselet, C. Foussard, et al.
High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial
J. Clin. Oncol., January 20, 2008; 26(3): 440 - 446.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A. Tzankov, S. Heiss, S. Ebner, W. Sterlacci, G. Schaefer, F. Augustin, M. Fiegl, and S. Dirnhofer
Angiogenesis in nodal B cell lymphomas: a high throughput study
J. Clin. Pathol., May 1, 2007; 60(5): 476 - 482.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D. Gratzinger, S. Zhao, R. J. Marinelli, A. V. Kapp, R. J. Tibshirani, A. S. Hammer, S. Hamilton-Dutoit, and Y. Natkunam
Microvessel Density and Expression of Vascular Endothelial Growth Factor and Its Receptors in Diffuse Large B-Cell Lymphoma Subtypes
Am. J. Pathol., April 1, 2007; 170(4): 1362 - 1369.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Farinha, H. Masoudi, B. F. Skinnider, K. Shumansky, J. J. Spinelli, K. Gill, R. Klasa, N. Voss, J. M. Connors, and R. D. Gascoyne
Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)
Blood, September 15, 2005; 106(6): 2169 - 2174.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
R. D. Gascoyne
Hematopathology Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas
Hematology, January 1, 2005; 2005(1): 299 - 306.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2005 by the American Association for Cancer Research.